PubMed
An exercise-inducible metabolite that increases endurance via the ERRγ pathway
Li et al., 2023
GLP-1 & MetabolicResearch OnlyC
SLU-PP-332
ERR Pan-Agonist
Exercise-mimetic metabolic research compound (non-peptide) explored for endurance pathways.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 4
- Research grade
- C
- Experience
- 56
- Activity
- 64
Overall check-ins
Trackers & reports
Overview
About SLU-PP-332
Exercise-mimetic metabolic research compound (non-peptide) explored for endurance pathways.
- Category
- GLP-1 & Metabolic
- Regulatory status
- Research Only
- Also known as
- ERR Pan-Agonist
- Self-reports
- 27
Community
What 27 users report
27 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
141
Appetite
141
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
137
Self-reported dose per injection
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.2 to ≥ 5 mg (open-ended top bucket)
0.2–0.4 mg
26
0.4–0.6 mg
2
0.6–1 mg
1
1–2 mg
5
2–3 mg
1
5+ mg
106
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 84% said they felt similar to their last entry, 16% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 94 days · Based on 25 repeat reporters
Research
Cited research (3)
Source
PubMed
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Billon et al., 2024
PubMed
Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling
Okda et al., 2026
Tools
Explore more
Explore
More ways to learn about SLU-PP-332 from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about SLU-PP-332?
This page summarizes 27 anonymized self-reports from PeptIQ users who track SLU-PP-332, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for SLU-PP-332?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for SLU-PP-332?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is SLU-PP-332 safe to use?
This wiki does not assess safety or recommend use. SLU-PP-332 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of SLU-PP-332?
Research, primarily in animal models, suggests SLU-PP-332 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of SLU-PP-332?
SLU-PP-332 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified SLU-PP-332 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of SLU-PP-332?
The safety and effectiveness of SLU-PP-332 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on SLU-PP-332?
While there are over 200 published studies on SLU-PP-332, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source